Program
HS-20117
A development code. Also written as “HS-20117 combined Platinum-containing chemotherapy”, “HS-20117+CAPEOX” and “HS-20117+FOLFIRI”.
In Hansoh Pharmaceutical Group's pipeline, EGFR/c-MET bispecific, PM1080
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 33 open or running | phase 3since May 12, 2024 | Jun 26, 2023 | none ahead |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20117 (EGFR/c-MET bispecific, PM1080)
, phase 1, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05940116 · 322 planned · China
- May 12, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06417008 · 1,080 planned · China
- Sep 29, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06621563 · 780 planned · China
TargetBeta
“EGFR/c-MET bispecific, PM1080”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06621563Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Mar 30, 2026 | 780 |
| NCT06417008Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jun 1, 2026 | 1,080 |
| NCT05940116Carcinoma, Non-Small-Cell Lung · China | 1 | Not yet recruiting | Jul 30, 2025 | 322 |
How it is read
Names in the registry
- “HS-20117”, 2 entries
- “HS-20117 combined Platinum-containing chemotherapy”, 1 entry
- “HS-20117+CAPEOX”, 1 entry
- “HS-20117+FOLFIRI”, 1 entry
- “HS-20117+mFOLFOX6”, 1 entry
Codes read as this program: HS20117.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.